Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02742103 · ClinicalTrials.gov registry record · Phase 2
A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT02742103 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 83 participants.
The verdict
NCT02742103, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This study is a phase 2, multicenter, double-blind, randomized, placebo controlled, parallel-group study to investigate the renal safety and tolerability of multiple dose intravenous (IV) administration of CSL112 compared with placebo in subjects with moderate renal impairment (RI) and acute myocardial infarction (AMI).
Interventions
- OTHER Placebo
- BIOLOGICAL CSL_112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02742103
The ClinicalTrials.gov registry entry for NCT02742103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02742103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02742103 about?
NCT02742103 is a clinical study titled "A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction". This study is a phase 2, multicenter, double-blind, randomized, placebo controlled, parallel-group study to investigate the renal safety and tolerability of multiple dose intravenous (IV) administration of CSL112 compared with placebo in subjects with moderate renal impairment (RI) and acute myocard...
What is the current status of trial NCT02742103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2016-08. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02742103?
The interventions under investigation include: Placebo (OTHER), CSL_112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02742103?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.